Oxler Private Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

Oxler Private Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$782K	Sell	1,575 -57	-3%	-$25.3K	0.22%	49
2026 Q1	$729K	Hold	1,632	–	–	0.23%	49
2025 Q4	$740K	Hold	1,632	–	–	0.21%	51
2025 Q3	$639K	Sell	1,632 -42	-3%	-$17.6K	0.19%	57
2025 Q2	$745K	Hold	1,674	–	–	0.23%	51
2025 Q1	$812K	Sell	1,674 -110	-6%	-$51.3K	0.29%	47
2024 Q4	$718K	Hold	1,784	–	–	0.24%	52
2024 Q3	$830K	Hold	1,784	–	–	0.29%	47
2024 Q2	$836K	Hold	1,784	–	–	0.31%	46
2024 Q1	$746K	Buy	+1,784	New	+$754K	0.29%	52
2023 Q4	–	Sell	-1,796	Closed	-$625K	–	93
2023 Q3	$625K	Hold	1,796	–	–	0.31%	61
2023 Q2	$632K	Sell	1,796 -101	-5%	-$34K	0.3%	65
2023 Q1	$598K	Hold	1,897	–	–	0.3%	66
2022 Q4	$548K	Hold	1,897	–	–	0.29%	66
2022 Q3	$549K	Hold	1,897	–	–	0.31%	69
2022 Q2	$535K	Buy	+1,897	New	+$508K	0.26%	76

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Oxler Private Wealth's VRTX Position: Q2 2026 in Review

Oxler Private Wealth reduced its Vertex Pharmaceuticals (VRTX) stake by 3.5% in Q2 2026, selling an estimated $25.3K and leaving 1,575 shares worth $782K. The position accounts for 0.22% of the portfolio, ranked #49.

Oxler Private Wealth first reported a position in VRTX in Q2 2022 and has held it in 16 quarters since. The position peaked at $836K in Q2 2024. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Oxler Private Wealth held 1,575 shares of Vertex Pharmaceuticals worth $782K as of Q2 2026.
Oxler Private Wealth sold 57 Vertex Pharmaceuticals shares in Q2 2026, an estimated $25.3K.
Vertex Pharmaceuticals made up 0.22% of Oxler Private Wealth's portfolio in Q2 2026, its #49 holding.
Oxler Private Wealth first reported a position in Vertex Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
Oxler Private Wealth's Vertex Pharmaceuticals position peaked at $836K in Q2 2024.
1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Oxler Private Wealth's 13F filing for Q2 2026, filed 3 Aug 2026.